Newcyte is a next generation umbilical cord-derived mononuclear cell product exclusively produced by a top biofirm lab following FDA cGMP regulations. Stem cell regenerative medicine has been an effective therapy for over ten years. However, little has changed in that time. Newcyte offers recently developed and innovative techniques that maximize cell viability documentd up by 11.8%, which enhances mesenchymal stem cell (MSC) function and growth factor preservation. Our cell product is obtained from fresh, healthy, donated neonatal tissue and minimally manipulated to yield unprecedented viability.

The Science of Stem Cells:

The only stem cell-based products that are FDA-approved for use in the United States consist of blood-forming stem cells derived from umbilical cord blood. GOVERNMENT REFERENCE


The Scientist Behind the cells:


Ian A. White, Ph.D.
Chief Scientific Officer

Dr. White is considered a leading expert in the field of regenerative medicine with 20 years’ experience working with stem cells. Dr. White received in BS and MS from Liverpool University, England prior to being hired at Dartmouth college to study the genetics of gamete biology. From there Dr. White was recruited to Harvard University to work with hematopoietic stem cells and immune cell biology under the mentorship of the world-renowned Dr. Laurie Glimcher, where he co-authored several high impact peer-reviewed scientific manuscripts on the subject. Dr. White went on to receive his Ph.D. from the Ansary Stem Cell Institute of Cornell University under the guidance of Dr. Shahin Rafii. During this time Dr. White developed an in vitro method for culture expanding autologous stem cells in an artificial vascular niche for the treatment of cancer patients who have undergone bone marrow ablation following chemo- or radio-therapy. This technology has since gone on to be commercialized by Cornell University and has been described in several co-authored manuscripts and research grants awarded by the NIH.

Since his Ph.D. Dr. White spent some time in the stem cell laboratory of Dr. Stephen Dalton, who’s pioneering work led to the inclusion of c-myc as one of the 4 factors used by Nobel award winning Dr. Shinya Yamanaka in the generation of induced pluripotent stem cells (iPSCs). The Dalton lab also played a key role in the development of STEMPRO™ stem cell culture media.

Subsequently, Dr. White relocated to the Interdisciplinary Stem Cell Institute at the University of Miami’s Miller School of Medicine. Dr. White published ground-breaking research in the field of regenerative medicine alongside Dr. Joshua Hare, including a book chapter on the use of Mesenchymal Stem Cells (MSCs) in Cardiology. In 2015 Dr. White’s work on the regeneration of the heart was featured on the cover of Circulation Research, one of the top peer-reviewed journals for cardiovascular medicine in the world. In 2016 Dr. White was honored with an award for the “Best Manuscript” by the American Heart Association for his work highlighting the role of peripheral nerves in cardiac regeneration. Dr. White has published extensively in the field of stem cell biology, clinical stem cell applications and regenerative medicine. Dr. White recently licensed a novel regenerative cell culture media, which he developed, to Kerafast for the purpose to ex vivo tissue regeneration.